A new chapter as Prognosis ends

Health Monitor is coming.

Read in browser

Note to readers: Today is Prognosis' final edition. On March 5, a new weekly newsletter, Health Monitor, will replace Prognosis for paying Bloomberg subscribers. If you are a subscriber, no action is required. If you are not currently a Bloomberg subscriber, you will stop receiving Prognosis and will instead receive Bloomberg's flagship Morning Briefing Americas newsletter, which offers a broader look at the day's most important news. To continue receiving dedicated health coverage and access more subscriber-only newsletters, explore a Bloomberg.com subscription. Hi, it's Anne in New York, where I've been editing Prognosis for a few years. This newsletter has morphed a few times during its lifetime, and it's about to do so again. More on that in a moment, but first ... Today's must-reads How health influencer Gary Brecka became the MAHA biohacking guru. Novo will make its Wegovy pill in Ireland for markets outside the US. Opinion: The FDA dismissal of Moderna's novel flu vaccine is bad for public health. New look Hello again, Prognosis readers. We've been through a lot in seven years. The newsletter was launched in April 2019 as a once-a-week feature highlighting Bloomberg reporting on health issues. That first edition explored the plunge in drug company and hospital stocks after Senator Bernie Sanders proposed a bill that would provide "Medicare for All." It also shared the happy news that gene therapy had cured eight infants with Bubble Boy Disease. In March 2020, just days before the World Health Organization declared that Covid-19 was a pandemic, Prognosis was rebranded as a daily coronavirus newsletter, offering updates on cases, death counts, government responses and, eventually, the remarkable vaccine breakthrough. As we emerged from pandemic lockdowns in June 2022, this newsletter changed again. It reclaimed its Prognosis name and returned to covering a broader range of health topics. These included other public health threats, like dengue fever, whooping cough and superbugs. We spotlighted Bloomberg's reporting on the rise of GLP-1 weight-loss drugs, the toll from cancer capitalism and investigations into private Medicare Advantage plans. And we detailed the Trump administration's upending of years of accepted public health policies. There was also news you could use. Are Birkenstocks good for your feet? (Mostly.) Is it safe to take Zyrtec every day? (Yes, but watch for drowsiness.) Should you rinse your chicken or turkey before roasting? (Absolutely not.) This is the last daily edition of the Prognosis newsletter. Starting Thursday, March 5, subscribers will receive Health Monitor, a once-a-week compendium highlighting our most important reporting. Please consider a Bloomberg.com subscription to continue reading — there's so much more ahead in science, medicine, care and costs. — Anne Cronin What we're reading America is losing its sense of mutual responsibility, and that's undermining public health, the Atlantic argues. RFK Jr. is making an election year pivot to talk up healthy eating instead of vaccine skepticism, the New York Times reports. Commercial dog foods can contain heavy metals, plastic and potential carcinogens, CNN reports. Contact Prognosis Have a tip that we should investigate? Contact us at AskPrognosis@bloomberg.net. Follow us You received this message because you are subscribed to Bloomberg's Prognosis newsletter. If a friend forwarded you this message, sign up here to get it in your inbox. Unsubscribe Bloomberg.com Contact Us Bloomberg L.P. 731 Lexington Avenue New York, NY 10022 |